Clinical features and treatment outcome in Japanese patients with social anxiety disorder: Chart review study

Psychiatry and Clinical Neurosciences

Volumn 60, Issue 4, 2006, Pages 410-416

  Shindo, Masanobu ^a   Shioiri, Toshiki ^b   Kuwabara, Hidki ^a   Maruyama, Maki ^a   Tamura, Ryu ^a   Someya, Toshiyuki ^b  

^a NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

Benzodiazepine; Fluvoxamine; Pharmacotherapy; Selective serotonin reuptake inhibitor; Social anxiety disorder (social phobia)

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CLOMIPRAMINE; CLONAZEPAM; CLOXAZOLAM; DIAZEPAM; ETIZOLAM; FLUVOXAMINE; LOFRAZEPATE; LORAZEPAM; PAROXETINE; SULPIRIDE; TANDOSPIRONE; UNCLASSIFIED DRUG; VALPROIC ACID;

ADOLESCENT; ADULT; CLINICAL FEATURE; CONTROLLED STUDY; DENTAL HEALTH; DRUG RESPONSE; FEMALE; GENERAL CONDITION IMPROVEMENT; GENERALIZED ANXIETY DISORDER; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; ONSET AGE; OUTPATIENT; PSYCHIATRIC DEPARTMENT; REVIEW; SCHOOL CHILD; SOCIAL PHOBIA; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

ADULT; AGE OF ONSET; ANTI-ANXIETY AGENTS; ANXIETY; FEMALE; HUMANS; JAPAN; MALE; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; SOCIAL ENVIRONMENT; TREATMENT OUTCOME;

EID: 33745961715     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2006.01524.x     Document Type: Review

References (22)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Text revision. APA, Washington, DC, 2000.
2. Yamada N, Nakajima S. DSM-III-R disorders in a large sample of psychiatric patients; frequency, sex difference and age. Seisinigaku 1996; 38: 767-775 (in Japanese).
3. Kaiya H, Yokoyama T, Tuchida H et al. Social anxiety disorder - Clinical characteristics and pharmacological practice in Japan. Rinsyo Seisin Yakuri 2003; 6: 1309-1320 (in Japanese).
4. Nagata T, Oshima A, Kiriike N et al. Predictors of response to pharmacotherapy in social anxiety disorder: retrospective chart study in relationship with firm belief (third) type and social withdrawal. Seisinigaku 2004; 46: 933-939 (in Japanese).
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. APA, Washington, DC, 1994.
6. Stein DJ. Pharmacotherapy of social anxiety disorder. Rinsyo Seisin Yakuri 2002; 5: 440-447 (in Japanese).
7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 3rd edn. revised. APA, Washington, DC, 1987.
8. Kessler RC, McGonagle KA, Zhao S et al. Life time and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch. Gen. Psychiatry 1994; 51: 8-19.
9. Weissman MM, Blnd RC, Canino GJ et al. The cross-national epidemiology of social phobia: a preminary report. Int. Clin. Psycopharmacol. 1996; 11 (Suppl.): 9.
10. Andrews G, Creamer M, Crino R et al. The Treatment of Anxiety Disorders: Clinician Guides and Patient Manuals, 2nd edn. Cambridge University Press, Cambridge, 2002.
11. Davidson JR, Hughes DL, George LK et al. The epidemiology of social phobia: findings from the Duke Epidemiological Catchment Area Study. Psychol. Med. 1993; 23: 709-718.
12. Katzelnick DJ, Kobak KA, Helstad CP et al. Impact of generalized social anxiety disorder in managed care. Am. J. Psychiatry 2001 December; 158: 1999-2007.
13. Schneier FR, Johnson J, Hornig CD et al. Social phobia: comorbidity and morbidity in an epidemiologic sample. Arch. Gen. Psychiatry 1992; 49: 282-288.
14. Sareen L, Stein M. A review of the epidemiology and approaches to the treatment of social anxiety disorder. Drugs 2000; 59: 497-509.
15. van Viet IM, den Boer J, Westenberg HGM. Psychopharmacological treatment of social phobia; a double-blind placebo controlled study with fluvoxamine. Psychopharmacology 1994; 15: 128-134.
16. Liebowitz MR. Social phobia. Mod. Probl. Pharmacopsychiatry 1987; 22: 141-173.
17. Stein MB, Fyer AJ, Davidson JR et al. Fluvoxamine treatment of social phobia (social anxiety disorder): a double blind, placebo controlled study. Am. J. Psychiatry 1999; 156: 756-760.
18. Harai H, Yoshida K, Okajima M et al. Evidences of pharmacotherapy for social anxiety disorder. Rinsyo Seisin Yakuri 2003; 6: 1303-1308 (in Japanese).
19. Stein MB, Liebowitz MR, Lydiard RB et al. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA 1998; 280: 708-713.
20. Fedoroff IC, Taylor S. Psychological and pharmacological treatments of social phobia: a meta analysis. J. Clin. Psychopharmacol. 2001; 21: 311-324.
21. van der Linden GJ, Stein DJ, van Balkom AJ. The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): a meta analysis of randomized controlled trials. Int. Clin. Psychopharmacol. 2000; 15 (Suppl. 2): S15-S23.
22. Blanco C, Antia SX, Liebowitz MR. Pharmacotherapy of social anxiety disorder. Biol. Psychiatry 2002; 51: 109-120.